Third Harmonic Bio reports $269.1M cash, files IND for THB335, Q4 net loss narrows

Third Harmonic Bio, Inc.

Cash and equivalents $269.1M as of Dec 31, 2023; expected to fund operations through at least 2026.
Net loss for Q4 2023 was $6.8M versus $11.5M in Q4 2022; full-year net loss $30.8M.
R&D expenses decreased to $5.9M in Q4 2023 from $9.3M year-over-year.
U.S. IND filed for THB335, a potential first-in-class oral KIT inhibitor for chronic spontaneous urticaria.
Phase 1 SAD/14-day MAD study in healthy volunteers anticipated to start in Q2 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Third Harmonic Bio, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income Net loss for the three months ended December 31, 2023 decreased to $6.8 million from a net loss of $11.5 million for the.

Period: fourth quarter and full year ended December 31, 2023
Net income: Net loss for the three months ended December 31, 2023 decreased to $6.8 million from a net loss of $11.5 million for the
Result: reported results

Exact text from the filing

Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-036162

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.